Mer­ck clears PFS end­point in con­fir­ma­to­ry tri­al for Keytru­da in clas­si­cal Hodgkin lym­phoma

Clas­si­cal Hodgkin lym­phoma was the first blood can­cer that Mer­ck’s Keytru­da was ap­proved to treat. Three years af­ter that OK ar­rived — kick­ing off a spate of new in­di­ca­tions for the star PD-1 in­hibitor — the com­pa­ny fi­nal­ly has some sol­id ev­i­dence of its ef­fect.

Build­ing on the over­all re­sponse rates that con­vinced FDA reg­u­lars to hand down an ac­cel­er­at­ed ap­proval in March 2017, Mer­ck said Keytru­da hit a co-pri­ma­ry end­point on pro­gres­sion-free sur­vival in the Phase III con­fir­ma­to­ry tri­al.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.